Treatment of Premature Ejaculation and Erectile Dysfunction

Initial Diagnostic Priorities

The American Urological Association recommends distinguishing between primary erectile dysfunction versus secondary premature ejaculation, as many men develop PE as a consequence of ED, either from anxiety about maintaining erections or from requiring intense stimulation to achieve adequate rigidity 1, 2
The European Association of Urology suggests that the sexual history must clarify whether ejaculation occurs before desired due to lack of control or loss of erection after normal ejaculation, and timing of premature ejaculation in relation to ED onset 1, 2
The intravaginal ejaculatory latency time (IELT) is a key factor in diagnosing PE, with self-estimated timing of ejaculation after penetration, and <2 minutes indicating PE 1, 3

The European Urology guidelines recommend initiating phosphodiesterase-5 inhibitors (PDE5-Is) as first-line therapy for erectile dysfunction, with options including sildenafil, tadalafil, or vardenafil, which have high efficacy and safety even in difficult-to-treat populations like diabetic patients 3
The American College of Cardiology suggests assessing cardiovascular risk before prescribing PDE5-Is, as high-risk profiles contraindicate sexual activity and PDE5-I use, and PDE5-Is are absolutely contraindicated with concurrent nitrate or riociguat use 3
Many patients experience resolution of premature ejaculation once erectile function improves, according to the Journal of Urology 1, 2

The European Urology guidelines recommend adding selective serotonin reuptake inhibitors (SSRIs) as the primary pharmacologic intervention if premature ejaculation persists after ED treatment, with all SSRI use for PE being off-label in the United States 1, 3, 4
Daily dosing SSRIs, such as paroxetine, sertraline, fluoxetine, or clomipramine, provide the most robust evidence for treating PE, according to the Journal of Urology 2
On-demand dapoxetine is the only agent approved for PE in Europe, taken 1-3 hours before sexual activity, although it is not FDA-approved in the US 3, 4

The American Urological Association suggests incorporating behavioral modifications and considering involving the sexual partner in treatment decisions, with shared decision-making optimizing outcomes 1, 4
Modifying sexual positions or practices to increase arousal and control can benefit both conditions, according to Praxis Medical Insights 4, 5
Referral to mental health professionals with sexual health expertise should be considered, particularly for lifelong PE, as recommended by Praxis Medical Insights 4

The FDA has not approved any medications specifically for premature ejaculation, and all pharmacotherapy is off-label use, according to the Journal of Urology and Praxis Medical Insights 1, 4
Patients require counseling about the off-label nature of treatment, weak evidence base for some interventions, potential for known and unknown side effects, and SSRI adverse effects, as recommended by Praxis Medical Insights 4, 5

The primary treatment outcome is patient and partner satisfaction, rather than arbitrary physiological measures, according to the Journal of Urology and Praxis Medical Insights 2, 5
The goals of treatment include regaining sense of control over ejaculation timing, achieving satisfaction with sexual intercourse for both partners, and reducing distress and interpersonal difficulties, as recommended by European Urology and the Journal of Urology 1, 3